Login to Your Account

Approval of Valchlor Triggers Actelion Merger for Ceptaris

By Peter Winter
BioWorld Insight Editor

Monday, August 26, 2013
Malvern, Pa.-based Ceptaris Therapeutics Inc. received FDA marketing approval for its single asset, Valchlor (mechlorethamine) gel, for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma, in patients who have received prior skin-directed therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription